Health-related quality of life based on the European Questionnaire 5D-5L utility score in patients with multidrug-resistant tuberculosis
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Patients' health-related quality of life (HRQOL) is negatively impacted by multidrug-resistant tuberculosis (MDR-TB). The HRQOL of MDR-TB patients was assessed in this study using the European Questionnaire 5D-5L (EQ-5D-5L) utility score and HRQOL-related parameters. We conducted a case-control study at the Haji Hospital from June to December 2024. MDR-TB patients and drug-sensitive (DS-TB) patients were divided into case and control groups, respectively. The HRQOL utility score and depression levels were measured using the Indonesian EQ-5D-5L and Patient Health Questionnaire-9 (PHQ-9), respectively. This study included 84 TB patients, 36 and 48 of whom had MDR-TB and DS-TB, respectively. Patients with DR-TB had a significantly higher PHQ-9 score (7.55±5.97 vs. 4.69±4.21; p=0.047) than patients with DS-TB. When compared to the control group, the case's EQ-5D-5L and EQ Visual Analog Scale utility scores were considerably lower, at 0.86±0.11 and 69.30±16.65 (p=0.005) against 0.92±0.07 and 80.70±15.53 (p=0.002), respectively. The EQ-5D-5L utility score was considerably lower in DR-TB patients with depression and a history of TB treatment. In conclusion, the HRQOL of MDR-TB patients was low. Among MDR-TB patients, depression and TB treatment history were associated with quality of life. This study provides insight into the need for healthcare practitioners to evaluate patients' HRQOL, particularly for those with risk factors.
Ethics approval
This study was authorized by the Haji Hospital's ethical committee for health research with approval number 445/149/KOM.ETIK/2024.How to Cite

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.